Clinical Trial Update: Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase II trial of venetoclax plus rituximab as initial therapy for older patients with mantle cell lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: TERMINATED